Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

Expanding research and development of naturally-derived psilocybin for future FDA IND-enabling and clinical studies TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announceContinue reading “Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds”

Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory

Numinus progresses on its ecosystem approach to the ultimate delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies  – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce it has begun cultivating Psilocybe mushrooms, for theContinue reading “Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory”

Liberty Leaf to Acquire Nova Mentis Biotech Corp. – Liberty Leaf Augments Portfolio with Entrance into the Emerging Psilocybin Therapy Market

– Liberty Leaf Holdings Ltd. (CSE: LIB) (FSE: HN3P) (OTCPK: LIBFF) (“LIB” or the “Company”) is pleased to announce that it has entered into an agreement (the “Agreement”) with Nova Mentis Biotech Corp. (“NOVA”), pursuant to which LIB will acquire, by way of share exchange, 100 per cent of all of the issued and outstanding securitiesContinue reading “Liberty Leaf to Acquire Nova Mentis Biotech Corp. – Liberty Leaf Augments Portfolio with Entrance into the Emerging Psilocybin Therapy Market”